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Objective. Chemokine receptors mediate leuko-
cyte migration into inflamed rheumatoid arthritis (RA)
synovial tissue (ST). Knowledge of their distribution is
crucial for understanding the evolution of the inflam-
matory process. In this study, we used rat adjuvant-
induced arthritis (AIA), a model for RA, to define the
temporospatial expression of chemokine receptors.
Methods. ST from rats with AIA was immuno-
stained, the percentage of cells expressing each receptor
was determined, and findings were correlated with levels
of inflammation. Chemokine receptor expression was
evaluated on rat macrophages in vitro.
Results. CCR1, a receptor for macrophage in-
flammatory protein 1 (MIP-1)/CCL3 and RANTES/
CCL5, exhibited high constitutive expression on macro-
phages in AIA. CCR5, binding MIP-1/CCL3 and
RANTES/CCL5, was up-regulated on ST macrophages
during the course of AIA, correlating with macrophage
expression of CCR2, a receptor for monocyte chemoat-
tractant protein 1/CCL2. Endothelial cell (EC) CCR2
was down-regulated as arthritis progressed, inversely
correlating with inflammation. CCR3, another
RANTES/CCL5 receptor, was constitutively high on
macrophages in vivo and in vitro, with down-regulation
during AIA. CXCR4, a receptor for stromal cell–derived
factor 1/CXCL12), was prominently up-regulated on
ECs, preceding the peak of inflammation.
Conclusion. These findings show that 1) constitu-
tive expression of CCR1 on macrophages remains high
during AIA; 2) CCR2 and CCR3 may play a role in
initial recruitment of leukocytes to ST in AIA; 3) mac-
rophage expression of CCR2 and CCR5 may be impor-
tant for sustaining inflammatory changes; and 4) EC
CXCR4 may be a harbinger of inflammatory changes.
Our results may help guide chemokine receptor
blockade–targeting treatment strategies in inflamma-
tory arthritis.
Rheumatoid arthritis (RA) is a chronic inflam-
matory disease characterized by infiltration of leuko-
cytes into the joint, mediated in part by chemokines (1).
Upon activation of the endothelium by proinflammatory
cytokines, leukocytes adhere to endothelial cells (ECs)
and subsequently transmigrate across the EC barrier
into the synovium.
Chemokines form a large family of small, struc-
turally and functionally related proteins that facilitate
chemoattraction and migration of leukocytes from the
circulation into sites of inflammation and promote an-
giogenesis, cell proliferation, and apoptosis (2,3). To
date, more than 50 chemokines have been defined based
on the number and spacing of cysteine residues in the
amino-terminal region; they are termed C, CC, CXC,
and CX3C chemokines (4).
The biologic activity of chemokines is mediated
via 7-transmembrane domain G protein–coupled recep-
tors (5). Twenty chemokine receptors have been identi-
fied and are denoted as CCR1–11, CXCR1–7, XCR1,
and CX3CR1 (6). Certain chemokine receptors bind
only a unique ligand and vice versa, while others are
more promiscuous. There is evidence that chemokine
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receptors are used sequentially, thereby serving a unique
function in the migratory process (7). The putative
complexity and redundancy emphasize the importance
of both spatially and temporally well-defined secretion
and presentation of chemokines and chemokine recep-
tors in the synovial tissue (ST), as well as regulated
expression of their counterparts on leukocytes during
differentiation and activation (8).
To determine the specific role of chemokine
receptors in the pathogenesis of RA and to design
interventional approaches accordingly, it is important to
understand the temporospatial expression of chemokine
receptors in the development of inflammatory arthritis.
The present study was undertaken to elucidate this.
MATERIALS AND METHODS
Induction of rat adjuvant-induced arthritis (AIA) and
tissue sampling. Female Lewis rats (100 gm) were injected
subcutaneously at the base of the tail with 300 l (5 mg/ml)
lyophilized Mycobacterium butyricum (Difco, Detroit, MI) in
sterile mineral oil on day 0. Rats were killed at various times
post–adjuvant injection, and joints harvested.
Immunohistochemistry. Immunohistochemistry stud-
ies were performed on ST cryosections (8 m) from rats with
AIA, for the chemokine receptors CCR5, CXCR4 (polyclonal
goat antibodies cross-reacting with human, mouse, and rat;
Santa Cruz Biotechnology, Santa Cruz, CA), CCR1, CCR2,
CCR3, CCR4 (polyclonal rabbit antibodies cross-reacting with
human, mouse, and rat; Santa Cruz Biotechnology), CXCR1,
CXCR2, CXCR3, and CXCR5 (monoclonal mouse anti-
human antibodies; R&D Systems, Minneapolis, MN). Anti-
body concentration was 2 g/ml for CCR1–5 and CXCR4, and
10 g/ml for CXCR1, CXCR2, and CXCR5. Isotype-matched
nonspecific IgG was used as a negative control. Immunostain-
ing was performed using Elite ABC kits (Vector, Burlingame,
CA) and diaminobenzidine (Kirkegaard & Perry, Gaithers-
burg, MD) as a chromogen, followed by counterstaining with
hematoxylin.
Microscopic analysis. ST elements examined included
lining cells, macrophages, ECs, lymphocytes, and smooth mus-
cle cells. Immunostaining was evaluated under blinded condi-
tions and graded by a pathologist as described previously (9).
Cell types were distinguished based on their characteristic
morphology and/or immunohistochemical staining reaction
(9–11). Macrophages were distinguished from fibroblasts
based on morphology and immunoreactivity with monoclonal
mouse anti-rat CD11b/c antibody (monocyte/macrophage
marker; BD PharMingen, Franklin Lakes, NJ). Endothelium
was verified using anti–von Willebrand factor (anti-vWF;
Dako, Carpinteria, CA), synovial lining cells were determined
based on morphologic features, and lymphocytes were identi-
fied by their characteristic nuclear morphology and chromatin
pattern. Each ST component was graded for frequency of
staining on a scale of 0–100%, where 0% indicates no staining
and 100% indicates that all cells were immunoreactive. The
percentage of reactivity was defined as the number of cells of
a given type reacting with a specific antibody divided by the
total number of cells of that given type. To confirm identifi-
cation of macrophages, CD11b/c-positive cells coexpressing
CCR1 and CXCR4 were determined using double staining.
Lymphocytes were identified by CD3 staining. In addition, an
inflammation score was obtained using the following scoring
system: 1  normal; 2  increased number of inflammatory
cells, arrayed as individual cells; 3  increased number of
inflammatory cells including distinct clusters (aggregates); and
4  marked diffuse infiltrate of inflammatory cells. Score data
were pooled, and the mean  SEM was calculated in each data
group.
Cell culture. NR8383 cells, a rat alveolar macrophage
cell line (American Type Culture Collection, Manassas, VA),
were maintained in Ham’s F-12 medium (Invitrogen, Carlsbad,
CA) containing 20% fetal bovine serum, 100 units/ml penicil-
lin, 100 g/ml streptomycin, and 2 mM glutamine at 37°C/5%
CO2. Cells (20,000/well) were cultured in 8-well Labtek cham-
ber slides (BD PharMingen) until confluence was reached. The
medium was changed to serum-free Ham’s F-12 before stim-
ulation for 3 hours with lipopolysaccharide (LPS; 10 g/ml)
(12).
Immunofluorescence. NR8383 cells were used for im-
munofluorescence staining after formalin fixation. Similarly,
double immunofluorescence analysis was performed on ST
from rats with AIA to determine colocalization of chemokine
receptors with synovial cells, using the EC-specific rabbit
anti-human vWF antibody, mouse anti-rat CD11b/c, or the T
cell marker CD3. After blocking, tissues or cells were incu-
bated with the primary antibodies for chemokine receptors,
cell type markers, or control IgG, respectively. For detection,
the following immunofluorescence dye–tagged secondary an-
tibodies (1:200 in phosphate buffered saline) were used: Alexa
Fluor 568–conjugated stained goat anti-rabbit antibody,
Alexa Fluor 488–conjugated donkey anti-rabbit antibody, and
Alexa Fluor 488–conjugated donkey anti-goat antibody (all from
Molecular Probes, Eugene, OR). Nuclear staining was performed
with 4,6-diamidino-2-phenylindole-dihydrochloride (Molecular
Probes). Immunofluorescence staining was detected using a
BX51 fluorescence microscope system (Olympus, Melville, NY)
with DP Manager imaging software. CD11b/c-positive cells in ST
from rats with AIA, reflecting the influx of monocyte/macro-
phages, were assessed by counting the number of cells in 5
high-power fields (hpf; 400) and calculating the average number
of cells per hpf. CD11b/c-coexpressing CCR1 and CXCR4 were
determined in the same way and presented as the percentage of
chemokine receptor–positive cells per CD11b/c-expressing cell.
Statistical analysis. Values are presented as the
mean  SEM. Statistical analysis was performed using Stu-
dent’s t-test. P values less than 0.05 were considered significant.
Pearson correlation coefficients were assessed to describe the
relationships of various parameters, using the mean from each
time point during AIA.
RESULTS
Course of inflammation in rat AIA. Rats with
AIA started showing clinical signs of inflammation on
days 7–14 post–adjuvant injection. Histologic assess
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Figure 1. Kinetics of histologic inflammation and expression of CCR1 in synovial tissue (ST) from rats with adjuvant-induced arthritis (AIA). A,
Inflammation score and expression of CCR1 by various cell types. Lining cells and macrophages (Ms) showed constitutive expression of CCR1.
The percentage of lining cells and macrophages that were immunopositive for CCR1 tended to be increased on day 25 (the time of maximum
inflammation of the joints), declining thereafter. Values are the mean and SEM. B, Results of double staining in relation to inflammation score.
Double staining with anti-CD11b/c using immunofluorescence confirmed the baseline expression of CCR1 in macrophages and revealed significant
up-regulation on day 25 post–adjuvant injection, with subsequent down-regulation. Values are the mean and SEM. C, Correlations between CCR1
expression and inflammation score during the course of AIA. Expression of CCR1 on lining cells correlated with the histologic inflammation score
over time and mirrored CCR1 staining on macrophages. n  number of time points. D, CCR1 expression by immunohistochemistry and
immunofluorescence in ST from rats on day 0 (prior to adjuvant injection). There was intense staining for CCR1 on macrophages compared with
staining with control IgG. Immunofluorescence costaining with anti-CD11b/c confirmed the high percentage of immunopositivity on macrophages,
but suggested that CCR1 was expressed not only on the cell surface, but also on the cytoplasm (arrows). Merge  overlay of CD11b/c and CCR1
staining; arrowheads indicate CD11b/c-positive cells that were negative for CCR1 (original magnification  100; the 2 smaller boxes show further
magnifications of the indicated areas [original magnification  250]).
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Figure 2. Kinetics of histologic inflammation and expression of CCR2 in ST and comparison with CCR2 expression in macrophages and smooth
muscle cells in rats with AIA. A, Inflammation score and expression of CCR2 by various cell types. Endothelial cells (ECs) constitutively expressed
CCR2. ST EC expression of CCR2 remained high in early AIA, but decreased dramatically by day 18, with the decrease persisting to day 25 (the
time of maximum inflammation of the joints) and an increase tending to occur thereafter. Macrophages showed only slight expression of CCR2, but
with a trend toward an increase on day 14. Values are the mean and SEM. B, CCR2 expression determined by immunohistochemistry in ST of a
rat with AIA compared with an IgG-treated control (inset) on day 14, showing occasional macrophage staining (black arrow) and intense EC staining
in the ST microvasculature (arrowheads). CD3 staining (as a marker for lymphocytes) on day 18 showed only occasional colocalization with CCR2
in inflammatory ST (white arrows). Merge  overlay of CD11b/c and CCR1 staining (original magnification  200 in left image [including inset];
original magnification  100 in right images). C, Course of EC expression of CCR2 in rat AIA, showing a negative correlation with the degree of
inflammation and with CCR2 expression on lining cells. n  number of time points. D, Percentages of macrophages stained for CCR1 and CCR2
during the course of rat AIA, indicating inverse expression of the 2 chemokine receptors over time. Smooth muscle cells that were immunopositive
for CCR1 and CCR2 in normal rats (day 0) are shown for comparison. CCR2 showed abundant constitutive expression (49  6%), and tended to
decrease on day 14 of AIA (23  14%), followed by a rebound on day 25. In contrast, CCR1 expression on normal ST smooth muscle cells was low,
but increased slightly on day 14 with a subsequent decline to baseline values. Values are the mean and SEM. See Figure 1 for other definitions. Color
figure can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
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ment, based on the appearance of infiltrating inflamma-
tory cells, demonstrated significant deterioration on day
18 (P  0.05), with peak inflammation on day 25 (Figure
1A). Immunofluorescence data on CD11b/c-positive
macrophages paralleled the inflammation score, show-
ing significant cell influx (P  0.05) starting on day 14
(mean  SEM 16  2 cells/hpf, compared with 8  1
cells/hpf in nonarthritic controls [day 0]), with further
increases on day 18 (20  4 cells/hpf) and day 25 (38 
6 cells/hpf) and a subsequent decline on day 54 (12  2
cells/hpf).
Up-regulation of constitutive CCR1 expression in
rat AIA. Among the important receptors in RA is CCR1,
with its ligands RANTES/CCL5 and macrophage inhib-
itory protein 1 (MIP-1)/CCL3. CCR1 expression in
ST macrophages was constitutive and showed an in-
crease on day 25 post–adjuvant injection (which was the
time of maximum joint inflammation), with a subsequent
decline to baseline expression on day 54, as determined
by both immunohistochemistry and immunofluores-
cence (Figures 1A and B). Surprisingly, lining cells also
exhibited major constitutive expression of CCR1, which
tended to increase at the peak of inflammation with a
subsequent decline, the number mirroring CCR1 expres-
sion on macrophages (r  0.86) (Figures 1A and C).
Expression of CCR1 on lining cells also correlated with
the histologic inflammation score (r  0.80) (Figure 1C),
while ECs and lymphocytes were nonreactive for CCR1
(data not shown).
Role of CCR2 in the initial recruitment of peri-
pheral blood monocytes to ST in rats with AIA. Macro-
phages in normal rat ST were only occasionally immu-
nopositive for CCR2, a receptor for monocyte
chemoattractant protein 1 (MCP-1)/CCL2, but in macro-
phages from rats with AIA, CCR2 levels tended to be
increased on day 14 post–adjuvant injection and there-
after (Figure 2A). In contrast, ST ECs showed constitu-
tive expression of CCR2 that remained high in early
AIA (Figures 2A and B), but decreased dramatically by
day 18 (with the decrease persisting to day 25 [at the
peak of inflammation] [P  0.05]) and tended to in-
crease thereafter. These data suggest a role for CCR2 on
ECs in early leukocyte recruitment and transendothelial
migration. Moreover, EC expression of CCR2 was in-
versely correlated with both the degree of inflammation
(r  0.85) and CCR2 expression on lining cells (r 
0.85) (Figure 2C). CD3 lymphocytes expressed
CCR2 only occasionally (Figure 2B).
Inverse correlation of CCR1 and CCR2 expres-
sion on ST in AIA. Figure 2D shows the interrelation of
CCR1 and CCR2 expression on macrophages and in
smooth muscle cells in rat AIA. Interestingly, the pat-
tern of expression of CCR2 on those cell types was
almost inverse to that of CCR1 expression on macro-
phages. This observation was corroborated by observa-
tions of CCR1 and CCR2 expression on smooth muscle
cells in ST of rats with AIA at different time points
compared with day 0. CCR2 was amply constitutively
expressed in smooth muscle cells but showed a trend
toward decreased immunoreactivity on days 7 and 14 of
AIA, followed by a slight rebound. In contrast, CCR1
expression on normal ST smooth muscle cells was low,
but increased on day 14 with a subsequent decline to
baseline values, underscoring the different time and
nature of action of the 2 receptors in leukocyte recruit-
ment and retention in rat AIA.
Role of CCR3 in early AIA in rats. CCR3, a
receptor for RANTES/CCL5 and eotaxin/CCL11, was
present on macrophages in rats with early AIA (mean 
SEM 42  11%), but expression tended to decrease
during the course of AIA (23  14% on day 18) (Figures
3A and B), supporting the notion of their initial involve-
ment in leukocyte recruitment to the joint. CCR3 ex-
pression on lining cells in ST of rats with AIA exhibited
a similar time course (Figure 3A), emphasizing the role
of the receptor in this context. Conversely, ECs barely
expressed CCR3, and lymphocytes did not show signifi-
cant immunopositivity (data not shown), as confirmed
by immunofluorescence costaining with CD3.
CCR4 expression on synovial endothelium pro-
motes leukocyte recruitment in rats with early AIA.
CCR4, a receptor for thymus and activation–regulated
chemokine (TARC)/CCL17 and macrophage-derived
chemokine (MDC)/CCL22, may be particularly impor-
tant for CD3,CD4 memory T cell migration to
synovium in RA (13,14). As shown in Figure 3C, consti-
tutive CCR4 EC expression was down-regulated as
inflammation progressed, supporting the idea that
CCR4 has a specific role in leukocyte recruitment in the
early phase of AIA. In contrast, CCR4 expression on
macrophages was weak and unaltered, coinciding with
the finding that ST lining cells and lymphocytes did not
express CCR4 in AIA (data not shown).
Importance of CCR5 expression on macrophages
for sustaining the inflammatory changes in rat AIA.
Investigators at our laboratory have shown previously
that CCR5, the receptor for RANTES/CCL5, MIP-1/
CCL3, and MIP-1/CCL4, is up-regulated at the protein
and messenger RNA (mRNA) levels on various ST cells
during peak inflammation in rat AIA (11). In the present
study we expanded those data by defining CCR5 expres-
sion at the protein level at different time points during
the course of AIA in the context of the expression
patterns of other chemokine receptors.
Rat ST macrophages exhibited weak constitutive
expression of CCR5 that tended to be up-regulated in
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AIA starting on day 7, with a significant increase on day
54 (P  0.05) (Figures 4A and B), suggesting a distinct
role for CCR5 and its ligands particularly in maintaining
the inflammatory process. CCR5 expression on macro-
phages correlated well with CCR5 immunoreactivity on
lining cells (r  0.90) and tended to have a course similar
to that of macrophage staining for CCR2 (r  0.76),
suggesting a close pathophysiologic relationship of the 2
chemokine receptors (Figure 4C). Immunofluorescence
analysis for CCR5 and CD11b/c on day 18 confirmed
colocalization of CCR5 in rat macrophages, revealing
both cytoplasmic and cell surface expression (Figure
4D). ECs showed only weak CCR5 expression, with a
moderate, but not statistically significant, increase in
early AIA (Figure 4A), while lymphocytes were essen-
tially immunonegative for the receptor (data not shown).
CXCR4 expression on ECs precedes the peak of
inflammation in rat AIA. CXCR4, the receptor for
stromal cell–derived factor 1 (SDF-1)/CXCL12 (which
plays a critical role in monocyte localization to inflamed
RA synovium [15], as well as in promoting neovascular-
ization in RA ST [16]), showed prominent expression on
ECs starting on day 14 (P  0.05) (Figure 5A). CXCR4
expression preceded the peak of inflammation and was
followed by a slow decline until day 54, emphasizing its
potential role in retention of inflammatory effector cells
in the joint (Figure 5A). Double immunofluorescence
studies for vWF and CXCR4 confirmed the endothelial
expression during the course of rat AIA (Figure 5C).
Normal macrophages (i.e., day 0) expressed minimal
CXCR4, but expression of the receptor on macrophages
was increased starting on day 18 of AIA (P  0.05)
(Figures 5A and B). In addition, immunofluorescence
staining revealed CXCR4 expression predominantly on
the cell surface (Figure 5D). In contrast, ST lining cells
expressed CXCR4 constitutively (mean  SEM 22 
9%), followed by significant CXCR4 down-regulation in
the early phase of AIA (P  0.05) (Figure 5A). Again,
lymphocytes in ST from rats with AIA only occasionally
expressed CXCR4, and costaining with the T cell marker
CD3 corroborated these findings (data not shown).
Chemokine receptor expression on stimulated
NR8383 cells reflects the in vivo situation in early AIA in
rats. To investigate whether expression of chemokine
receptors on rat macrophages in vitro reflects in vivo
conditions and if expression changes in response to a
proinflammatory stimulus, we used the rat macrophage
cell line NR8383 to determine baseline expression and
intracellular distribution before and after stimulation
with LPS (Figure 6A). NR8383 cells showed intense
constitutive, predominantly cytoplasmic, expression of
CCR1 which was not affected by LPS stimulation,
corroborating the in vivo data. NR8383 cells demon-
Figure 3. Kinetics of histologic inflammation and expression of CCR3
and CCR4. A, Inflammation score and expression of CCR3 by various cell
types. CCR3 was constitutively expressed on rat macrophages (42  11%)
and lining cells (25  18%), but its expression tended to decrease during
rat AIA, with a rebound on days 25–54. Endothelial cells barely expressed
CCR3, except later in the course of AIA. Values are the mean and SEM.
B, CCR3 expression determined by immunohistochemistry in ST of a rat
with AIA compared with an IgG-treated control (inset) on day 14,
showing intense staining for CCR3 on lining cells (arrowheads) and
macrophages (arrows) (original magnification  200). C, Percentages of
various cell types stained for CCR4 on day 25 and day 54 in rats with AIA,
compared with findings in normal rats (day 0). While constitutive endo-
thelial cell CCR4 expression was significantly down-regulated during
inflammation, no major changes were observed regarding CCR4 expres-
sion on macrophages and lining cells. Values are the mean and SEM. See
Figure 1 for definitions. Color figure can be viewed in the online issue,
which is available at http://www.arthritisrheum.org.
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strated less CCR2 expression both with and without LPS
stimulation, also paralleling the results obtained for
CCR2 staining on normal and AIA ST. Likewise, CCR4
could not be detected on NR8383 cells in vitro (results
not shown), while high constitutive cell surface expres-
sion of CCR3 showed a slight decrease in response to
LPS. Surprisingly, stimulation of quiescent NR8383 cells
resulted in clear up-regulation of CCR5. In contrast, a
faint but distinct cell surface pattern for CXCR4 essen-
tially did not change after LPS treatment.
CXCR1 expression on smooth muscle cells in rat
ST. Immunohistochemistry analysis for CXCR1 in nor-
mal rat ST (Figure 6B) showed constitutive expression
on smooth muscle cells (mean  SEM 9  7%), which
tended to be decreased on day 18 of rat AIA (4  3%)
and thereafter (2  1% on day 54). Conversely, in lining
cells and macrophages, CXCR1 expression was in-
creased during rat AIA compared with expression in
normal rats (P  0.05 for macrophages on day 18).
Role of CXCR2, CXCR3, and CXCR5 in rat
synovium. Evaluation of additional CXC chemokine
receptors in normal and arthritic rat ST demonstrated
expression only on lining cells and macrophages (Figure
6C), but virtually no staining on ECs or lymphocytes
(data not shown). CXCR2, a receptor for the human
chemokines growth-related oncogene /CXCL1 and
Figure 4. Kinetics of histologic inflammation and expression of CCR5 in ST from rats with AIA. A, Inflammation score and expression of CCR5
by various cell types. Low constitutive CCR5 expression on macrophages showed a trend toward up-regulation during AIA, and was significantly
increased on day 54. A similar pattern was observed for CCR5 on ST lining cells. Endothelial cells showed weak CCR5 expression, with a moderate
increase in early AIA that was not statistically significant. Values are the mean and SEM. B, CCR5 expression determined by immunohistochemistry
in ST of a rat with AIA compared with an IgG-treated control (inset) on day 18, showing macrophage staining (arrows), as well as CCR5-positive
lining cells (arrowheads); asterisk indicates adjacent bone (original magnification  200). C, Correlations of CCR5 expression on macrophages with
CCR2 expression on macrophages and with CCR5 staining on lining cells during the course of AIA. Macrophage CCR5 staining clearly mirrored
lining cell CCR5 staining and correlated with macrophage CCR2 staining. n  number of time points. D, Double immunofluorescence staining for
the macrophage marker CD11b/c and CCR5, showing colocalization after merging (arrows). Counterstaining was performed with 4,6-diamidino-
2-phenylindole-dihydrochloride (DAPI) (original magnification  200). See Figure 1 for other definitions. Color figure can be viewed in the online
issue, which is available at http://www.arthritisrheum.org.
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Figure 5. Kinetics of histologic inflammation and expression of CXCR4 in ST from rats with AIA. A, Inflammation score and expression of CXCR4
by various cell types. Compared with nonarthritic controls (day 0), endothelial cells (ECs) showed prominent CXCR4 expression on day 14,
preceding the peak of inflammation and declining thereafter. ST lining cells, which constitutively expressed CXCR4, exhibited decreased expression
of this receptor in early AIA, while CXCR4 expression on macrophages tended to increase in late AIA. Values are the mean and SEM. B, Results
of double staining in relation to inflammation score. Double staining with anti-CD11b/c using immunofluorescence confirmed the observation of low
baseline CXCR4 expression on macrophages with a subsequent significant increase starting on day 18. Values are the mean and SEM. C, Double
immunofluorescence for the EC marker von Willebrand factor (vWF) and CXCR4. Merging of the two revealed colocalization (arrow in lower right
image). Arrows in upper right image indicate CXCR4 staining not associated with ECs; arrowheads in upper left and lower right images indicate
ECs not positive for CXCR4. Counterstaining was performed with 4,6-diamidino-2-phenylindole-dihydrochloride (DAPI) (original magnification 
100). D, CXCR4 expression by immunohistochemistry in ST of a rat with AIA compared with an IgG-treated control on day 18, showing macrophage
staining (arrows in upper left and lower left images) and positive staining on ECs (arrowheads). Double immunofluorescence staining with
anti-CD11b/c revealed CXCR4 expression on macrophages predominantly on the cell surface (arrows in lower right image) (original magnifica-
tion  200). See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
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epithelial neutrophil–activating protein 78/CXCL5 or
the rat homologs cytokine-induced neutrophil chemoat-
tractant 1/CXCL1 and LPS-induced CXC chemokine/
CXCL5, tended to increase during the inflammatory
phase of rat AIA, on day 18. CXCR3, a receptor for
interferon-–inducible 10-kd protein (IP-10)/CXCL10
and monokine induced by interferon- (Mig)/CXCL9
showed a similar trend on lining cells, while CXCR5, a
Figure 6. Chemokine receptor expression in the rat macrophage cell line NR8383 and expression of CXCR on ST from rats with AIA. A,
Immunofluorescence staining for chemokine receptors on NR8383 cells, without stimulation and after stimulation with lipopolysaccharide (LPS; 10
g/ml), showing intense constitutive cytoplasmic expression for CCR1, very low baseline expression for CCR2, and distinct cell surface expression
for CXCR4, none of which was significantly altered by LPS. IgG isotype was used as a control (inset). High baseline expression for CCR3, showing
immunopositivity predominantly on the cell surface, was only slightly affected by LPS stimulation. Stimulation of quiescent NR8383 cells resulted
in a dramatic up-regulation of CCR5, with a clear cell surface pattern (original magnification  1,000). B, Percentages of various cell types stained
for CXCR1 on day 18 and day 54 in rats with AIA, compared with findings in normal rats (day 0). CXCR1 was constitutively expressed on smooth
muscle cells, followed by a decline during rat AIA. Conversely, lining cells showed a trend toward increased CXCR1 expression over time, and
macrophages showed de novo expression of CXCR1 on day 18 of rat AIA, which was significant compared with findings in normal rat ST
macrophages. Values are the mean and SEM. C, Trends in CXCR2, CXCR3, and CXCR5 expression on lining cells and macrophages in ST from
rats with AIA on day 18 and day 54 post–adjuvant administration, compared with day 0. Values are the mean. See Figure 1 for other definitions.
Color figure can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
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receptor for B cell–attracting chemokine 1/CXCL13,
showed baseline expression on lining cells with a trend
toward a decrease during the course of AIA.
DISCUSSION
Chemokines and their receptors have increas-
ingly been considered to be interesting potential targets
for therapy in RA (17). The prevailing paradigm is that
leukocyte influx into the joint is orchestrated through a
sophisticated network of expressed chemokine receptors
and their ligands. Thus, knowledge of defined expression
patterns is needed in order to develop means of blocking
chemokine interactions with their receptors, thus modi-
fying the inflammatory process.
In human RA, CCR1-positive cells, mainly macro-
phages, are scattered throughout the synovium (14).
Studies of CCR1 disruption in mice have yielded con-
flicting results regarding inflammatory responses, with
both abrogation (18) and enhancement (19) being ob-
served. However, blocking of CCR1 ligands resulted in
impaired monocyte migration in vitro in response to RA
SF and in reduced synovial inflammation and joint
destruction in rodent models of RA (20,21). Moreover,
a double-blind, placebo-controlled, phase Ib clinical trial
using an oral CCR1 antagonist showed improved histo-
logic features in ST of patients with RA (17).
In our study, constitutive CCR1 expression on ST
lining cells tended to increase at the time of maximum
inflammation in AIA. ST macrophages also showed
constitutive expression of CCR1, with a significant in-
crease at the time of peak inflammation on day 25,
supporting findings in human RA (14). Surprisingly, we
observed cytoplasmic and cell surface expression of
CCR1 both in vivo and in vitro, potentially indicating a
yet-unknown function of this receptor. These results
suggest that CCR1 has a distinct role in recruiting and
retaining leukocytes in rat AIA, and underscore our
recent finding that blocking of CCR1 in rat AIA signif-
icantly reduced joint inflammation and monocyte/
macrophage influx (22). These data also parallel findings
on the fractalkine receptor CX3CR1 in rats, i.e., lack of
EC staining but high constitutive macrophage staining,
maintained during AIA (10).
CCR2 is expressed on T cells and monocytes
infiltrating human RA ST (23). In studies of blocking of
the CCR2 ligand MCP-1/CCL2, there was partial im-
provement of murine arthritis (24). Surprisingly, in a
collagen-induced arthritis (CIA) model, the disease was
worse in CCR2 gene–deficient mice compared with
wild-type controls (25); this suggested that CCR2 can
serve as a negative regulator of arthritis onset and
severity, conflicting with the current paradigm and im-
plicating a more variable role of CCR2 than initially
anticipated. In the present study, CCR2 protein expres-
sion was occasionally observed in macrophages from
normal rat ST and tended to increase slightly on day 14
of AIA and thereafter, while expression of CCR2
mRNA in the whole joint has been shown to be clearly
up-regulated at the time of maximum inflammation (11).
Interestingly, immunoreactivity for CCR2 on
ECs was high constitutively as well as in early AIA, but
had decreased dramatically by day 18 post–adjuvant
administration, correlating negatively with the degree of
inflammation. This distinctive expression of a chemo-
kine receptor on endothelium, varying over time, may
result in temporospatially specific leukocyte adhesion
and transmigration, thus controlling the inflammatory
process (26). Recently, Dzenko et al showed that CCR2
expression by ECs is critical for macrophage transendo-
thelial migration in the brain (27). Our findings suggest
that CCR2 on ECs mediates leukocyte recruitment in
early AIA by facilitating transendothelial migration of
mononuclear cells, but may function in a different way at
a later time point. This notion of a dual role is supported
by the results of a study in which blockade of CCR2
during the early phase of CIA resulted in improved
clinical signs of arthritis and histologic scores, whereas
arthritis was aggravated following CCR2 blockade in
late stages of CIA (28).
Of note, on macrophages and smooth muscle
cells, CCR2 expression and CCR1 expression displayed
inverse patterns over time, thereby indicating essentially
different roles of the 2 chemokine receptors in recruiting
and retaining leukocytes in rat AIA. Both CCR1 and
CCR2 have previously been reported to be expressed by
human vascular smooth muscle cells in vitro (29), which
could explain the ability of smooth muscle cells to
respond to certain chemokines, thereby modifying pro-
liferation and migration. The significance of this obser-
vation in the context of RA, however, needs further
evaluation.
CCR3 was initially thought to be specific for
eosinophils but was subsequently identified to mediate T
cell recruitment (30). CCR3 has been demonstrated to
be moderately expressed on CD14 peripheral blood
monocytes in patients with RA, while normal control
subjects showed minimal expression (14), thereby indi-
cating a potential role of CCR3 in monocyte recruit-
ment. In the present study, CCR3 was detected on ST
macrophages and lining cells in early AIA with a subse-
quent trend toward declining expression, supporting the
idea of initial involvement in leukocyte trafficking to the
synovial joint. High constitutive expression of CCR3 on
rat ST macrophages was confirmed in experiments with
resting rat macrophages in vitro, with only a slight
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decrease after LPS stimulation, reflecting the in vivo
situation.
CCR4, initially thought to be restricted to T cells
and basophils, has subsequently been detected on peri-
pheral blood monocytes of RA patients (14). In human
RA ST, however, CCR4 was not detected on macro-
phages (14). Findings of other studies support the idea
that CCR4 may be crucial to the pathogenesis of RA
(13,31), although only limited data on the role of the
CCR4 ligands TARC/CCL17 and MDC/CCL22 are
available (32,33). The weak expression of CCR4 on
synovial macrophages as well as its virtual absence on
lining cells in rat AIA are supportive of the hypothesis
that this receptor does not have an essential proinflam-
matory role, despite the observation that total CCR4
mRNA expression in joints increased during rat AIA
(11). In some studies, CCR4 has even been considered
to have an antiinflammatory role (14,34). In contrast,
constitutive CCR4 expression in ECs was significantly
down-regulated during inflammation, suggesting a pos-
sible role of CCR4 in leukocyte recruitment and trans-
migration in the early phase of AIA. Interestingly,
CCR4-deficient mice are resistant to LPS-induced en-
dotoxic shock, indicating a defect in macrophage func-
tion (35). It would be very informative to observe the
effect of CCR4 deletion in an arthritis model.
Of particular interest regarding therapeutic inter-
vention in RA is CCR5, although in a recent study the
course of CIA was not significantly modified in CCR5-
deficient mice (25). However, in a nonhuman primate
model of RA, treatment with a CCR5 antagonist re-
sulted in clinical improvement of the disease (36),
supporting the notion that this chemokine receptor has
a pathogenic role in arthritis and providing strong
evidence for the potential value of therapy targeting this
receptor.
In the present study, CCR5 expression on syno-
vial macrophages showed a trend toward up-regulation
starting on day 7, with significantly increased levels of
CCR5-immunopositive macrophages on day 54, con-
firming observations in ST of humans with RA (14).
CCR5 expression on lining cells showed a similar pat-
tern, with protein expression following up-regulation of
CCR5 in the joint at the mRNA level (11). These data
suggest a distinct role for CCR5 and its ligands, partic-
ularly in maintaining the inflammatory process. How-
ever, CCR5 up-regulation on rat macrophages in re-
sponse to LPS, together with increased CCR5
expression in vivo, may indicate an important pathophys-
iologic role over time in arthritis. An array-based analy-
sis of not-yet-inflamed joints in mice with autoimmune
arthritis identified CCR5 as one of the most highly
up-regulated genes (37). In addition, mice that were
deficient for the CCR5 ligand MIP-1/CCL3 exhibited
milder arthritis (38). We also recently showed that
blocking of CCR5 in rat AIA resulted in reduced joint
destruction (22). Taken together, these findings indicate
that CCR5 targeting is an interesting potential therapeu-
tic approach, possibly in later rather than earlier stages
of inflammatory arthritis.
SDF-1/CXCL12 has been demonstrated to be
highly expressed in RA ST, and expression of its recep-
tor, CXCR4, was observed on CD4 T cells following
their entry into the synovium (39,40). Surprisingly, we
did not detect substantial CXCR4 expression on lym-
phocytes in ST from rats with AIA, suggesting that
murine lymphocytes may play a different role than in
human RA. Similarly, we demonstrated in an earlier
study that CX3CR1 was virtually absent on lymphocytes
during rat AIA (10), although it was clearly expressed on
human T cells in the arthritic joint (13). In contrast,
CXCR4 was prominently expressed on ST ECs in rat
AIA, starting on day 14 and preceding the inflammatory
peak. Likewise, Burman and coworkers found high
expression of the ligand SDF-1/CXCL12 on vascular
endothelium in inflamed RA ST (41). The expression of
both receptor and ligand on ECs indicates a potential
self-perpetuating pro-angiogenic mechanism, possibly
via autocrine expression of vascular endothelial growth
factor (42). Also, these data support the notion of a
potential role of CXCR4 in retention of inflammatory
effector cells and transendothelial migration in the joint,
thereby driving the inflammatory process (43). EC ex-
pression of different chemokines may result in direc-
tional migration of leukocytes (26), with CXCR4 being a
crucial part of this intercellular communication.
Macrophages showed increased expression of
CXCR4 starting on day 18 after AIA induction. Simi-
larly, CXCR4 has been implicated in monocyte localiza-
tion to inflamed RA ST (15). In our study, ST lining cells
expressed CXCR4 constitutively, followed by down-
regulation of CXCR4 in the early phase of AIA, sug-
gesting a self-limiting process.
Interestingly, immunohistochemistry analysis re-
vealed a cytoplasmic staining pattern for CXCR4, while
immunofluorescence clearly identified the receptor on
the cell surface. This is consistent with previous obser-
vations, reflecting the limitations of the detection
method used (10,11). Additional in vitro experiments
using the rat macrophage cell line NR8383 confirmed
the predominant cell surface expression not only of
CXCR4 but also of other receptors. Expression in
response to LPS essentially paralleled the in vivo situa-
tion in early rat AIA. Thus, NR8383 cells may be a
useful in vitro tool to study the inflammatory response in
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rat AIA, as previously shown for other inflammatory
diseases (12,44).
Human interleukin-8 (IL-8)/CXCL8 is known to
mediate inflammation in RA, and there is some evi-
dence for a role for its receptor, CXCR1, in RA (45).
Although CXCR1 is present in rats, a rodent homolog of
IL-8/CXCL8 has not been identified. In our study,
CXCR1 was constitutively expressed on smooth muscle
cells, with a subsequent decrease during AIA. As with
CCR1 and CCR2, the role of the CXCR1 that is
substantially constitutively expressed on synovial smooth
muscle cells remains unclear. Conversely, lining cells and
macrophages showed increased CXCR1 expression dur-
ing the course of arthritis, indicating a possible role in
maintaining the inflammatory process.
Results of staining for CXCR2 on both lining
cells and macrophages suggested a potential role in the
inflammatory phase, consistent with data regarding me-
diation of inflammation in RA by its ligands, likely via
promotion of angiogenesis (46). The chemokines IP-10/
CXCL10 and Mig/CXCL9 have been detected in human
RA (47), with their receptor CXCR3 demonstrated on
ECs in inflamed tissue (48). However, in the present
study, staining for CXCR3 failed to reveal substantial
expression on macrophages or ECs in rat ST, implying
that this receptor may be part of leukocyte ingress in
inflamed synovium only if expressed on the recruited
cells.
A recent study demonstrated reduced severity of
CIA in mice in response to inhibition of the CXCR5
ligand CXCL13 (49), which indicated a potential role for
CXCR5 in inflammatory arthritis. CXCR5 was also
found to be up-regulated in human RA synovium (50).
Indeed, in our study, CXCR5 was also present on lining
cells in normal and arthritic rat ST and showed minor
expression on macrophages.
In summary, this study provides information on
cell type–specific protein expression of CC and CXC
chemokine receptors during the course of rat AIA. This
knowledge of the temporospatial expression of chemo-
kine receptors may help to optimize target-oriented
blocking of chemokine receptors at different phases of
inflammatory arthritis.
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